Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of MU-G2GL01 for GD2-positive advanced or recurrent solid tumors
jRCT2033250044Phase 1Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MU-G2GL01 in Nonhematologic neoplasms and Not applicable (2 cohorts), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Tolerability and Safety. Started May 2026; status: recruiting.
02
Drugs
MU-G2GL01
03
Conditions
Nonhematologic neoplasmsNot applicable
Beyond the preview
Go deeper on jRCT2033250044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033250044.